MGRX
Mangoceuticals, Inc. Common Stock
NASDAQ: MGRX · HEALTHCARE · HEALTH INFORMATION SERVICES
$0.34
+2.56% today
Updated 2026-04-30
Market cap
$6.79M
P/E ratio
—
P/S ratio
14.88x
EPS (TTM)
$-2.17
Dividend yield
—
52W range
$0 – $3
Volume
15.5M
Mangoceuticals, Inc. Common Stock (MGRX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
0 of 8
Last 8 quarters
Avg EPS surprise
—
Last 4 quarters
Revenue YoY growth
-10.3%
Most recent quarter
EPS YoY growth
+83.9%
Most recent quarter
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+17.5%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+29.1%
2025-12-31
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.17 | — | $0.66 | $0.85 | +29.1% |
| 2025-11-14 | $-0.69 | — | $1.19 | $1.26 | +5.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | — | $-0.17 | — | $94360.00 | -10.3% |
| 2025-09-30 | — | $-0.69 | — | $84246.00 | -36.8% |
| 2025-06-30 | — | $-0.54 | — | $168109.00 | +3.0% |
| 2025-03-31 | — | $-1.05 | — | $109306.00 | -48.9% |
| 2024-12-31 | — | $-1.08 | — | $105247.00 | -56.9% |
| 2024-09-30 | — | $-0.99 | — | $133368.00 | -45.6% |
| 2024-06-30 | — | $-1.37 | — | $163163.00 | +15.5% |
| 2024-03-31 | — | $-1.56 | — | $214095.00 | — |
| 2023-12-31 | — | $-1.80 | — | $244374.00 | — |
| 2023-09-30 | — | $-1.70 | — | $245160.00 | — |
| 2023-06-30 | — | $-2.05 | — | $141237.00 | — |
| 2023-03-31 | — | $-0.23 | — | — | — |
Frequently asked questions
Has Mangoceuticals, Inc. Common Stock beaten earnings estimates?
Mangoceuticals, Inc. Common Stock has beaten Wall Street EPS estimates in 0 of its last 8 quarterly reports.
How does MGRX stock react to earnings?
MGRX stock has moved an average of +17.5% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.
What is Mangoceuticals, Inc. Common Stock's revenue growth rate?
Mangoceuticals, Inc. Common Stock reported year-over-year revenue growth of -10.3% in its most recent quarter, with EPS growing +83.9% year-over-year.